Novel potassium channel activators. III. Synthesis and pharmacological evaluation of 3,4-dihydro-2H-1,4-benzoxazine derivatives: Modification at the 2 position

Chemical and Pharmaceutical Bulletin

Volumn 48, Issue 3, 2000, Pages 428-432

  Matsumoto, Yuzo ^a,b   Uchida, Wataru ^a   Nakahara, Hideaki ^a   Yanagisawa, Isao ^a   Shibanuma, Tadao ^a   Nohira, Hiroyuki ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b SAITAMA UNIVERSITY   (Japan)

Author keywords

1,4 benzoxazine; Antihypertensive; Cromakalim; Nitrate activity; Nitroglycerine; Potassium channel activator

Indexed keywords

2 (3,4 DIHYDRO 3 HYDROXYMETHYL 2 METHYL 6 NITRO 2H 1,4 BENZOXAZIN 4 YL)PYRIDINE OXIDE; ANTIHYPERTENSIVE AGENT; BENZOXAZINE DERIVATIVE; HYDROXYL GROUP; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DOG; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RABBIT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY ANALYSIS;

EID: 0034082766     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.48.428     Document Type: Article

References (34)

1. For previous papers in this series see: a) Part I: Matsumoto Y., Tsuzuki R., Matsuhisa A., Takayama K., Yoden T., Uchida W., Asano M., Fujita S., Yanagisawa I., Fujikura T., Chem. Pharm. Bull., 44, 103-114 (1996);
2. b) Part II: Matsumoto Y., Tsuzuki R., Matsuh sa A., Masuda N., Yamagiwa Y., Yanagisawa I., Shibanuma T., Nohira H., ibid., 47, 971-979 (1999).
3. Gopalakrishnan M., Janis R. A., Triggle D. J., Drug Devel. Res., 28, 95-127 (1993).
4. Ulrich Q., Trens Pharmacol Sci. 14, 332-337 (1993).
5. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21-28 (1988);
6. b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91-100;
7. c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431-435 (1989):
8. d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529-1541 (1990);
9. e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417-422 (1990);
10. f) Evans J. M., Longman S. D., Ann. Reports Med. Chem., 1991, 73-82;
11. g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73-148 (1992);
12. h) Atwal K. S., Drug Devel. Res., 33, 250-262 (1994);
13. i) Evans J. M., Taylor S. G., Prog. Med. Chem., 31, 411-446 (1994);
14. j) Pirotte B., Fontaine J., Lebrun P., Cur. Med. Chem., 2, 573-582 (1995).
15. Raeburn D., Karlson J.-A., Prog. Drug. Res., 37, 161-180 (1991).
16. Edwards G., Henshaw M., Miller M., Weston A. H., Br. J. Pharmacol., 102, 679-686 (1991).
17. Buhl A. E., Waldon D. J., Conrad S. J., Mulholland M. J., Shull K. L., Kubicek M. F., Johnson G. A., Brunden M. N., Stefanski K. J., Stehle R. G., Gadwood R. C., Kamdar B. V., Thomasco L. M., Schostarez H. J., Schwartz T. M., Diani A. R., J. Invest. Dermatol., 98, 315-319 (1992).
18. Escande D., Cavero I., Trnds Pharmacol. Sci., 13, 269-272 (1992).
19. Hamilton T. C., Beerahee A., Moen J. S., Price P. K., Ramji J. V., Clapham J. C., Cardiovascular Drug Rev., 11, 199-222 (1993).
20. Ashwood V. A., Buckingham R. E., Cassidy F., Evans J. M., Faruk E. A., Hamilton T. C., Nash D. J., Stemp G., Willcocks K., J. Med. Chem., 29, 2194-2201 (1986);
21. Peterson H. J., Nielsen C. K., Martelli E. A., J. Med. Chem., 21, 773-781 (1978).
22. Sakai K., Jpn. J. Pharmacol., 30, 881-890 (1980).
23. Brown T. J., Chapman R. F., Cook D. C., Hart T. W., Mclay I. M., Jordan R., Mason J. S., Palfreyman M. N., Walsh R. J. A., Withnall M. T., Aloup J. C., Cavero I., Farge D., James C., Mondot S., J. Med. Chem., 35, 3613-3624 (1992).
24. Cho H., Katoh S., Sayama S., Murakami K., Nakamshi H., Kajimoto Y., Ueno H., Kawasaki H., Aisaka K., Uchida I., J. Med. Chem., 39, 3797-3805 (1996).
25. Koga H., Sato H., Imagawa J., Ishizawa T., Yoshida S., Sugo I., Taka N., Takahashi T., Nabata H., Bioorg. Med. Chem. Lett., 3, 2005-2010 (1993).
26. Lee B. H., Yoo S. E., Shin H. S., J. Cardiovasc. Pharmacol., 31, 85-94 (1998).
27. Shin H. S., Seo H. W., Yoo S. E., Lee B. H., Pharmacology, 56, 111-124 (1998).
28. Russell K., Brown F. J., Warwick P., Forst J., Grant T., Howe B., Kau S. T., Li J. H., McLaren F. M., Shapiro H. S., Trivedi S., Bioorg. Med. Chem. Lett., 3, 2727-2728 (1993).
29. Uchida Y., Sugimoto T., Myakkangaku., 24, 133-143 (1984).
30. Yanagisawa T., Okada Y., Cardiovasc. Drug Rev., 11, 94-115 (1993).
31. Nakajima T., Izawa T., Kashiwabara T., Nakajima S., Munezuka Y., Chem. Pharm. Bull., 42, 2475-2482 (1994).
32. Hashimoto K., Kinoshita M., Ohbayashi Y., Cardiovasc. Drugs Ther., 5, 131-138 (1991).
33. Cassidy F., Evans J. M., Smith D. M., Stemp G., Edge C., Williams D. J., J. Chem. Soc., Chem. Commun., 1989, 377-378.
34. Crystal structure analysis package, Molecular Structure Corporation (1985 & 1992).